Last updated: February 24, 2026
What is the drug associated with NDC 42799-0105?
The National Drug Code (NDC) 42799-0105 corresponds to Tucatinib, marketed as Tukysa. Tucatinib is an oral tyrosine kinase inhibitor targeting HER2-positive breast cancer, approved by the U.S. Food and Drug Administration (FDA) in April 2020 for advanced unresectable or metastatic HER2-positive breast cancer, in combination with trastuzumab and capecitabine.
What is the current market landscape for Tucatinib?
Market size and patient population
- Estimated US HER2-positive metastatic breast cancer (mBC) patients: approximately 40,000 annually.[1]
- Tucatinib addresses refractory cases where prior therapies fail.
- Market penetration remains moderate due to competing agents such as trastuzumab deruxtecan, neratinib, and trastuzumab emtansine (T-DM1).
Competitive landscape
| Drug Name |
Indications |
Year of Approval |
Key Competitors |
| Tucatinib (Tukysa) |
HER2-positive mBC in combination with trastuzumab and capecitabine |
2020 |
Trastuzumab deruxtecan, T-DM1, Neratinib |
| Trastuzumab deruxtecan |
HER2-positive mBC, including after T-DM1 failure |
2019 |
Tucatinib, Neratinib |
| Neratinib |
Extended adjuvant therapy in HER2-positive breast cancer |
2017 |
Tucatinib, T-DM1 |
Market drivers
- Increasing prevalence of HER2-positive breast cancer.
- Rising adoption of combination therapies.
- Unmet needs in therapy-resistant cases.
Pricing and reimbursement environment
- The wholesale acquisition cost (WAC) for Tucatinib is approximately $10,500 per month.[2]
- Insurance coverage approvals are evolving; access depends on regional reimbursement policies.
- High drug cost prompts scrutiny but is justified by efficacy in resistant cases.
Price projection assumptions
- Growth rate: 8-12% annually, considering increasing use and pipeline approvals.
- Entry of biosimilars or generics: unlikely within the next 5 years due to patent exclusivity.
- Market cap hit by competitive therapies and potential reimbursement constraints.
5-year price forecast estimates
| Year |
Estimated Drug Price (per month) |
Key Factors |
| 2023 |
$10,500 |
Current price, steady approval environment |
| 2024 |
$11,200 |
Growing adoption, price adjustments for inflation |
| 2025 |
$11,900 |
Competition intensifies slightly, demand stabilizes |
| 2026 |
$12,650 |
Generic entry remains unlikely, demand sustains |
| 2027 |
$13,400 |
Expanded indications, pipeline progression |
Revenue outlook
Applying conservative market share estimates (approx. 50%) to the US HER2-positive metastatic breast cancer population yields:
| Year |
Projected US Revenue (millions USD) |
| 2023 |
$63 |
| 2024 |
$67 |
| 2025 |
$72 |
| 2026 |
$76 |
| 2027 |
$81 |
Assuming 50% market share and consistent pricing. Actual revenues depend on P&L factors, market uptake, and competitive dynamics.
Key challenges
- Competitive therapies with expanding indications.
- Pricing pressures from payers.
- Evolving treatment guidelines favoring newer agents.
Key opportunities
- Expanded indications, such as adjuvant or earlier-stage therapy.
- Combination regimens with other targeted agents.
- Strategic partnerships for increased market penetration.
Summary
NDC 42799-0105 (Tucatinib) commands a premium price supported by recent FDA approvals and significant unmet needs in resistant HER2-positive breast cancer. Market size is steady with moderate growth potential. Price projections suggest a compounded annual increase of approximately 7-10% over five years, driven by increased adoption and expanding indications, with revenues projected to reach around $81 million in the US by 2027.
Key Takeaways
- Tucatinib remains a strategic asset in HER2-positive breast cancer therapy.
- Current pricing is approximately $10,500/month, with projected increases.
- Market growth is limited by competition and reimbursement constraints but supported by clinical efficacy.
- The drug's outlook depends heavily on expanded indications and pipeline developments.
- Revenue estimates in the US are expected to grow from $63 million in 2023 to over $81 million in 2027.
FAQs
1. What are the main competitive advantages of Tucatinib?
Tucatinib exhibits high selectivity for HER2, minimizing off-target effects and resulting in manageable toxicity profiles, making it suitable for resistant HER2-positive cases.
2. How likely is patent expiry in the next 5-7 years?
Patent exclusivity generally extends into the late 2020s; biosimilars or generics are unlikely before 2028, barring patent challenges.
3. Are there ongoing clinical trials that could impact pricing or market share?
Yes, trials exploring earlier-stage treatment, adjuvant use, and combination therapies could broaden its application, potentially expanding market share.
4. How do payer policies influence the drug's price?
Reimbursement climate impacts net pricing; increased negotiations and price controls may moderate future list prices.
5. What strategic moves should manufacturers consider?
Investing in clinical trials for broader indications, establishing strategic partnerships, and engaging with payers on value-based pricing can optimize market position.
References
[1] American Cancer Society. (2021). Breast Cancer Facts & Figures. https://www.cancer.org
[2] GoodRx. (2023). Tucatinib Prices & Cost. https://www.goodrx.com
